Methods of diagnosing cardiovascular disease

• US 20060099608A1
• Filed: 03/11/2005
• Published: 05/11/2006
• Est. Priority Date: 03/29/2004
• Status: Abandoned Application

• Current Assignee: MedStar Health Research Institute, Inc.
• Original Assignee: MedStar Research Institute, Inc.
• Inventors: Burnett, Mary Susan, Epstein, Stephen E.
• Application Number:
  US11/078,743
• Publication Number:
  US 20060099608A1
• Time in Patent Office: Days
• US Class Current: 435/6.16
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin G01N2333/665, corticotropin G01N2333/695
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 2800/324 Coronary artery diseases, e.g. angina pectoris, myocardial infarction
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

The invention relates to predicting which individuals are at risk of developing atherosclerotic vascular disease, and once having disease, which individuals are at risk of experiencing plaque rupture which, depending on the site of the plaque, could produce myocardial infarction, stroke, critical limb ischemia, or other vascular event. The invention further relates to methods of diagnosing and aiding in the diagnosis of vascular conditions such as atherosclerosis, premature coronary artery disease and coronary artery disease, by detecting a resistin gene product in an individual. The invention further relates to methods of predicting, and aiding in predicting, the likelihood that an individual will experience a vascular event, such as but not limited to, a myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack (TIA), or critical limb ischemia.

Claims

1. A method of diagnosing or aiding in the diagnosis of a vascular condition in an individual, the method comprising

(a) determining the level of a resistin gene product in a biological sample obtained from the individual;

and

(b) comparing the level with a control level, wherein if the level determined in (a) is greater than the control level, the individual is diagnosed as having the vascular condition.

2. The method of claim 1, wherein the biological sample is selected from the group consisting of whole blood, serum and plasma.

3. The method of claim 1, wherein the resistin gene product is a resistin polypeptide.

4. The method of claim 3, wherein the resistin polypeptide is a monomer, homodimer, homotrimer or homohexamer.

5. The method of claim 1, wherein determining the level of a resistin gene product in a biological sample comprises determining the level of a resistin polypeptide having a post-translational modification.

6. The method of claim 1, wherein the resistin gene product is a resistin mRNA.

7. The method of claim 1, wherein determining the level of the resistin gene product in the biological sample comprises determining the bioactivity of a resistin polypeptide in the sample.

8. The method of claim 1, wherein the control level is the average level of the resistin gene product in a population of individuals afflicted with a vascular condition.

9. The method of claim 1, wherein the control level is an average level of the resistin gene product in a population of one or more individuals afflicted with premature coronary artery disease.

10. The method of claim 1, wherein the vascular condition is selected from the group consisting of atherosclerosis, premature coronary artery disease (PCAD) and coronary artery disease (CAD).

11. The method of claim 10, wherein atherosclerosis is selected from cardiovascular atherosclerosis, cerebrovascular atherosclerosis, peripheral vessel atherosclerosis and coronary heart atherosclerosis.

12. The method of claim 1, wherein the vascular condition is a vascular event.

13. The method of claim 12, wherein the vascular event is selected from the group consisting of stroke, unstable angina, tachycardia, vasodilatation, palpitations, syncope heart stroke, clots, unstable angina, cardiac arrest, myocardial infarction, coronary death, non-fatal myocardial infarction, deep venous thrombosis, pulmonary embolism and transient ischemic attack.

14. The method of claim 1, wherein step (a) uses an immunological assay to determine the level of the resistin gene product.

15. The method of claim 14, wherein the immunological assay is a sandwich assay.

16. The method of claim 14, wherein the immunological assay uses a monoclonal antibody having a high affinity for resistin.

17. The method of claim 1, further comprising determining the level of at least one additional gene product in the sample, wherein the additional gene product is selected from the group consisting:

Annexin V, B-type natriuretic peptide (BNP), enolase, Troponin I (TnI), cardiac-troponin T, Creatine kinase (CK), Glycogen phosphorylase (GP), Heart-type fatty acid binding protein (H-FABP), Phosphoglyceric acid mutase (PGAM) S-100, soluble tumor necrosis factor-α

receptor-2, interleukin-6, and lipoprotein-associated phospholipase A2, C-reactive protein (CRP), Creatine Kinase with Muscle and/or Brain subunits (CKMB), thrombin anti-thrombin (TAT), soluble fibrin monomer (SFM), fibrin peptide A (FPA), myoglobin, thrombin precursor protein (TPP), platelet monocyte aggregate (PMA), troponin, homocysteine, myeloperoxidase (MPO), anti-HSP60 antibodies and HSP70.

18. The method of claim 1, further comprising determining the level of at least one additional gene product in the sample, wherein the additional gene product is a marker which is indicative of atherosclerotic plaque rupture and selected from the group consisting of:

human neutrophil elastase, inducible nitric oxide synthase, lysophosphatidic acid, malondialdehyde-modified low density lipoprotein, matrix metalloproteinase-1, matrix metalloproteinase-2, matrix metalloproteinase-3, matrix metalloproteinase-9, myeloperoxidase (MPO) and anti-HSP60 antibodies.

19. The method of claim 1, further comprising determining the level of at least one additional gene product in the sample, wherein the additional gene product is a marker which is indicative of coagulation and selected from the group consisting of:

β

-thromboglobulin, D-dimer, fibrinopeptide A, platelet-derived growth factor, plasmin-α

-2-anti-plasmin complex, platelet factor 4, prothrombin fragment 1+2, P-selectin, thrombin-antithrombin III complex, thrombus precursor protein, tissue factor and von Willebrand factor.

20. The method of claim 1, further comprising determining the level of at least one additional gene product in the sample selected from the group consisting of adiponectin, leptin and adrenomedullin.

21. A method for predicting the likelihood that an individual will develop a vascular condition, the method comprising

(a) determining the level of a resistin gene product in a biological sample obtained from the individual;

and

(b) comparing the level with a control level, wherein if the level determined in (a) is greater than the control level, the individual is said to have increased likelihood of experiencing the vascular event.

22. The method of claim 21, wherein the biological sample is selected from the group consisting of whole blood, serum and plasma.

23. The method of claim 21, wherein the resistin gene product is a resistin polypeptide.

24. The method of claim 23, wherein the resistin polypeptide is a monomer, homodimer, homotrimer or homohexamer.

25. The method of claim 21, wherein determining the level of a resistin gene product in a biological sample comprises determining the level of a resistin polypeptide having a post-translational modification.

26. The method of claim 21, wherein the resistin gene product is a resistin mRNA.

27. The method of claim 21, wherein determining the level of the resistin gene product in the biological sample comprises determining the bioactivity of a resistin polypeptide in the sample.

28. The method of claim 21, wherein the control level is the average level of the resistin gene product in a population of individuals afflicted with a vascular condition.

29. The method of claim 21, wherein the control level is an average level of the resistin gene product in a population of one or more individuals afflicted with premature coronary artery disease.

30. The method of claim 21, wherein the vascular condition is selected from the group consisting of atherosclerosis, premature coronary artery disease (PCAD) and coronary artery disease (CAD).

31. The method of claim 30, wherein atherosclerosis is selected from cardiovascular atherosclerosis, cerebrovascular atherosclerosis, peripheral vessel atherosclerosis and coronary heart atherosclerosis.

32. The method of claim 21, wherein the vascular condition is a vascular event.

33. The method of claim 32, wherein the vascular event is selected from the group consisting of stroke, unstable angina, tachycardia, vasodilatation, palpitations, syncope heart stroke, clots, unstable angina, cardiac arrest, myocardial infarction, coronary death, non-fatal myocardial infarction, deep venous thrombosis, pulmonary embolism and transient ischemic attack.

34. The method of claim 21, wherein step (a) uses an immunological assay to determine the level of the resistin gene product.

35. The method of claim 34, wherein the immunological assay is a sandwich assay.

36. The method of claim 34, wherein the immunological assay uses a monoclonal antibody having a high affinity for resistin.

37. The method of claim 21, further comprising determining the level of at least one additional gene product in the sample, wherein the additional gene product is selected from the group consisting:

Annexin V, B-type natriuretic peptide (BNP), enolase, Troponin I (TnI), cardiac-troponin T, Creatine kinase (CK), Glycogen phosphorylase (GP), Heart-type fatty acid binding protein (H-FABP), Phosphoglyceric acid mutase (PGAM) S-100, soluble tumor necrosis factor-α

receptor-2, interleukin-6, and lipoprotein-associated phospholipase A2, C-reactive protein (CRP), Creatine Kinase with Muscle and/or Brain subunits (CKMB), thrombin anti-thrombin (TAT), soluble fibrin monomer (SFM), fibrin peptide A (FPA), myoglobin, thrombin precursor protein (TPP), platelet monocyte aggregate (PMA), troponin, homocysteine, myeloperoxidase (MPO), anti-HSP60 antibodies and HSP70.

38. The method of claim 21, further comprising determining the level of at least one additional gene product in the sample, wherein the additional gene product is a marker which is indicative of atherosclerotic plaque rupture and selected from the group consisting of:

human neutrophil elastase, inducible nitric oxide synthase, lysophosphatidic acid, malondialdehyde-modified low density lipoprotein, matrix metalloproteinase-1, matrix metalloproteinase-2, matrix metalloproteinase-3, matrix metalloproteinase-9, myeloperoxidase (MPO) and anti-HSP60 antibodies.

39. The method of claim 21, further comprising determining the level of at least one additional gene product in the sample, wherein the additional gene product is a marker which is indicative of coagulation and selected from the group consisting of:

β

-thromboglobulin, D-dimer, fibrinopeptide A, platelet-derived growth factor, plasmin-α

-2-anti-plasmin complex, platelet factor 4, prothrombin fragment 1+2, P-selectin, thrombin-antithrombin III complex, thrombus precursor protein, tissue factor and von Willebrand factor.

40. The method of claim 21, further comprising determining the level of at least one additional gene product in the sample selected from the group consisting of adiponectin, leptin and adrenomedullin.